Hormone receptor positive HER2-negative/MammaPrint high-2 breast cancers closely resemble triple negative breast cancers

Researchers evaluated data from 742 patients with HER2- breast cancer to assess clinical and molecular differences among HR+ HER2- MammaPrint high-risk 1 (MP-H1), HR+ HER2- MammaPrint very high-risk high-2 (MP-H2), triple-negative MP-H1, and triple-negative MP-H2 cancers. The results showed similar transcriptional and clinical features between HR+ HER2- MP-H2 cancers and triple negative MP-H2 breast cancers. The researchers concluded that these subtypes could benefit from similar treatment strategies.